Evogene Ltd. cash flow to debt ratio of -614.29% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Evogene Ltd.'s free cash flow has increased -32.91% from $-20.33M last year to $-13.64M, signaling increasing performance

Evogene Ltd.'s debt to equity ratio is -0.80, signaling that the company spent its equity and risk bankruptcy.

Evogene Ltd.'s debt to equity ratio is -0.80, signaling that the company spent its equity and risk bankruptcy.

Evogene Ltd. has a net cash position, so leverage is healthy.

Evogene Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

Evogene Ltd.'s profit margin has decreased (116.31%) in the last year from -295.59% to -639.39%, signaling decreasing performance

Evogene Ltd.'s short-term assets of $15.63M exceed its short-term liabilities of $3.44M

Evogene Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Evogene Ltd.'s return on equity of 937.72%, is higher than 15.00%, indicating good performance

Evogene Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Evogene Ltd. had positive net income in only 0 out of 5 years, indicating unstable earnings

Evogene Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Evogene Ltd. has negative free cash flow, indicating cash burn

Evogene Ltd.'s yearly earnings has increased -48.53% since last year from $-16.48M to $-8.48M, signaling increasing performance

Evogene Ltd.'s yearly revenue has decreased 54.73% since last year from $8.51M to $3.85M, signaling decreasing performance

ROIC -100.84% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Evogene Ltd.'s 3-year revenue CAGR of 32.01% is positive, indicating growing revenue over the past 3 years

Evogene Ltd. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Evogene Ltd. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Evogene Ltd. has insufficient data to evaluate this check.

Evogene Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Evogene Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Evogene Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Evogene Ltd. is overvalued relative to its fair value price of -70.61 based on Earnings Fair Value model

Evogene Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Evogene Ltd. has a price-to-book ratio of 0.77x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Evogene Ltd. has a price-to-sales ratio of 3.33x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue